⚠️

Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.

Read our methodology →

Insia RizviM.D.

Hematology-Oncology · Chicago, IL 60612

NPI: 1073040895

Share:

43

🟠 Elevated

Risk Flags

Extreme opioid rate vs specialty peers99th percentile opioid prescribingElevated cost per beneficiary

Risk indicators are statistical patterns, not allegations. Learn more

214

Total Claims

$178K

Drug Cost

37

Beneficiaries

$4,798

Cost/Patient

Risk Score Breakdown 43/100

Low (0)Moderate (15)Elevated (30)High (50+)
Opioid rate vs specialty peers+25
Opioid rate (national percentile)+15
Cost per patient outlier+3

Score components are additive. Read full methodology

Peer Comparison vs. 8,541 Hematology-Oncology providers

+980%

Opioid rate vs peers

67.8% vs 6.3% avg

-65%

Cost per patient vs peers

$4,798 vs $14K avg

+34%

Brand preference vs peers

19.6% vs 14.6% avg

⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.

🔎 Data Overview

⚠️

Opioid prescribing rate is 980% above the average for Hematology-Oncology providers. While some providers legitimately treat pain-heavy populations, deviations of this magnitude are rare and warrant examination.

Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.

Opioid Prescribing

67.8%

Opioid Rate

145

Opioid Claims

$3,703

Opioid Cost

27.6%

Long-Acting Rate

This provider's opioid prescribing rate of 67.8% is above the 20% threshold that CMS considers elevated.

Brand vs Generic

80% generic

Brand: 42 claims · $174K

Generic: 172 claims · $3,899

Patient Profile

44

Avg Age

68%

Female

5.47

Avg Risk Score

Explore More

Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About